FDA extended its safety measure to screen whole blood and blood components for the Zika virus to all states and U.S. territories, not just areas with active Zika transmission. The agency recommends blood be screened with a test authorized for use under an investigational new drug application, a licensed test when available or an FDA-approved pathogen-reduction device for plasma and certain platelet products. The agency says that certain states should implement these recommendations as soon as feasible, but not later...